Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest antibodies Stories

2012-04-27 06:23:30

WALTHAM, Mass., April 27, 2012 /PRNewswire/ -- X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced it will present novel methods of selecting for antibodies against targets on the surface of live cells at CHI's Protein Engineering Summit (PEGS) and the associated Biologics Partnering Forum being held April 28th through May 4th in Boston, Massachusetts. Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY, will present a talk entitled,...

2012-04-26 02:27:53

TARRYTOWN, N.Y., April 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the first quarter of 2012 and provided an update on development programs. The Company reported total revenues of $232 million in the first quarter of 2012, which include EYLEA( )net product sales of $124 million. The Company reported non-GAAP net income of $40 million, or $0.37 per diluted share, in the first quarter of 2012. Non-GAAP net...

2012-04-24 09:41:06

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease affecting over five million people worldwide, and is the leading cause of dementia in the elderly. Currently, intravenous human immunoglobulin (IVIG) treatment is being explored in multiple off-label uses other than immunotherapy, including AD. Several clinical studies assessing the tolerability and efficacy of IVIG in Alzheimer's disease subjects are in progress with inconsistent outcomes. Recent studies...

2012-04-23 22:30:57

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry–one acutely sensitive to changes in the body that may be harbingers of illness. Now, Brian Andrew Chase and Barten Legutki, under the guidance of Stephen Albert Johnston, director of the Center for Innovations in Medicine at Arizona...

2012-04-22 23:01:25

Leading secondary reagents supplier offers secondary antibody conjugates West Grove, PA (PRWEB) April 22, 2012 Leading secondary antibodies supplier, Jackson ImmunoResearch, has new secondary antibody conjugates made with a selection of Alexa Fluor® dyes from Life Technologies. This offering includes AffiniPure antibodies and other proteins conjugated with Alexa Fluor® 647, Alexa Fluor® 594, and the very bright Alexa Fluor® 488. Each product table now lists the Alexa...

2012-04-19 02:29:45

MONROVIA, Calif., April 19, 2012 /PRNewswire/ -- Xencor, Inc. announced today that the Company received a milestone payment under an antibody optimization collaboration agreement with CSL Limited. The payment was triggered by filing of an investigational new drug application with the FDA for a novel monoclonal antibody that was optimized using Xencor's XmAb® antibody engineering technology. This is the first XmAb candidate to move into human clinical testing under the agreement with CSL...

2012-04-17 02:27:41

DALLAS, April 17, 2012 /PRNewswire/ -- ReportsnReports adds new market research report "Strategic Analysis of the U.S. Research Antibodies Market" to its store. This research service evaluates the U.S. research antibodies market during the 2009 to 2016 time period. The research antibodies market includes all antibodies sold for research use only to be used as assay components for detection and quantification of particular targets within a sample. Provided within the study is a...

2012-04-11 05:44:16

(Ivanhoe Newswire) -- A new study suggests that women who have been infected by two variations of HIV may have a better chance of suppressing the virus then those only infected with one. More than 1.1 million Americans are estimated to be living with HIV today, and every nine-and-a-half minutes someone in the U.S. becomes infected, according to the U.S. Department of Health and Human Services. An HIV vaccine is considered the best approach to long-term protection from HIV infection, but...

2012-04-10 02:27:38

IRVINE, Calif., April 10, 2012 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies, is pleased to announce that they will be launching a new antibody against CAIX, a marker of hypoxia that shows great promise for cancer research. (Photo: http://photos.prnewswire.com/prnh/20120410/LA84602) (Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) Hypoxia in tumors is closely associated with tumor aggressiveness and resistance to radio- and chemotherapeutic...

2012-04-10 02:26:17

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch(TM) technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of palivizumab, a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells. Palivizumab is used to reduce RSV associated...